Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vivoryon Therapeutics N.V. has emphasized the urgent need for novel treatments in kidney disease, despite recent advances, at their Kidney Disease KOL Event. Their lead asset, varoglutamstat, shows promise in targeting inflammatory and fibrotic pathways, particularly in diabetic kidney disease patients. The company is optimistic about varoglutamstat’s potential based on evidence from the VIVIAD Phase 2b study and looks forward to advancing clinical studies.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.